- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months ABERDEEN, Scotland and SINGAPORE, Dec. 1, 2022 /PRNewswire/ TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. As a hallmark of the disease, it is recognised as a key target for disease modifying treatments. This approach by TauRx contrasts to many in t
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY
Drug court, veterans court and drugs like laws. what keeps me up at night is first of all, the mass shootings we are seeing across the country and it is heartbreaking and terrifying. what keeps me up at night and what keeps mayors up at night is the day-to-day casual violence that is happening in american cities that it often times is proliferated by handguns. the u.s. conference of mayors from across the country met just a few months ago in reno, nevada, to talk about innovative gun violence intervention strategies and we are hoping that a lot of the strategies will get the funding necessary from the bill. you lead a b lucidity in a red state and you said some of the state laws passing here, regardless of what you re doing at the city level, make it less safe. tell us why.
LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published researchSafety profile
Very difficult time come november. build back better that they are arguing with, to say it s transformational, talk about build back better, it is swollen. that is why mansion and cinema went against the president. they had because nobody wanted it, even the people that wanted what was in it, said wait a second, what about all this other jelly? this is a very, very bad i pick that what the president can do is just stay the course. coronavirus, it s all about the virus, it s all about mixing this thing. he s got to speak with some determination, some clarity, and lucidity. geraldo, he didn t even do anything today. he had nothing on his schedule. let me ask you he didn t do anything today. 50% of america doesn t think he s doing anything with covid. do you agree with geraldo? i think that joe biden is the